What is EAGLE PHARMS INC's earnings per share (EPS)?

EAGLE PHARMS INC (EGRX) reported diluted earnings per share of $2.73 for fiscal year 2022. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

EAGLE PHARMS INC (EGRX) Financials

EGRX

Trailing 12 months to June 30, 2023

Revenue $257.6M -5.4% YoY

Net Income $11.9M -47.6% YoY

EPS (Diluted) $0.91 -48.6% YoY

Free Cash Flow -$9.4M -126.6% YoY

Market Cap $3.3M as of Oct 22, 2026

Price / Sales 0.0x on $257.6M revenue, trailing 12 months to June 30, 2023

Price / Earnings 0.3x on $11.9M net income, trailing 12 months to June 30, 2023

Price / Book 0.0x on $252.0M equity, Q2 FY2023

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2023, ended Jun 30, 2023 Reported Aug 9, 2023 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2023, filed Aug 9, 2023. Each column of the statement tables below links to the filing it was taken from.

EAGLE PHARMS INC (EGRX) reported $257.6M in revenue over the twelve months to Jun 30, 2023, down 5.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EGRX FY2022 2026-10-04

Eagle’s 2022 rebound restored profitability, but expansion made the balance sheet more working-capital-heavy and less liquid.

Operating margin rose to 25.6% even as gross margin fell to 73.0%, indicating the rebound came from the below-gross-profit cost structure rather than improved product economics. Operating cash flow of $50.7M nearly matched free cash flow of $50.5M, showing that routine fixed-asset spending was not consuming reported operating cash.

Total assets expanded to $406M from $254M, showing the 2022 rebound required a much larger operating base. Liabilities reached $173M while the current ratio fell to 1.7x, making short-term funding less comfortable than before.

Investing activities used $87M while capital expenditures were only $178K, implying most deployment was outside routine plant and equipment. That separate investment outflow helps explain why the company’s cash-generation profile looks stronger in operations than in total cash movement.

Financial Health Signals

Financial health score not available

EAGLE PHARMS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Grey Zone

2.06

EAGLE PHARMS INC scores 2.06, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from revenue of $316.6M against total assets of $406.2M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

EAGLE PHARMS INC passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed

1.42x

For every $1 of reported earnings, EAGLE PHARMS INC generates $1.42 in operating cash flow ($50.7M OCF vs $35.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

20.01x

EAGLE PHARMS INC earns $20.01 in operating income for every $1 of interest expense ($81.0M vs $4.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$64.6M

YoY-12.8%

QoQ-2.5%

5Y CAGR+1.7%

EAGLE PHARMS INC generated $64.6M in revenue in Q2 2023. This represents a decrease of 12.8% from the same quarter a year earlier. Against the prior quarter it is down 2.5%.

EBITDA

$10.4M

YoY+333.0%

QoQ-12.4%

EAGLE PHARMS INC's EBITDA was $10.4M in Q2 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 333.0% from the same quarter a year earlier. Against the prior quarter it is down 12.4%.

Net Income

$5.2M

YoYn/m

QoQ-10.2%

EAGLE PHARMS INC reported $5.2M in net income in Q2 2023. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 10.2%.

EPS (Diluted)

$0.39

YoYn/m

QoQ-11.4%

5Y CAGR+18.1%

EAGLE PHARMS INC earned $0.39 per diluted share (EPS) in Q2 2023. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 11.4%.

Cash & Balance Sheet

Free Cash Flow

-$132K

YoY-100.3%

QoQn/m

10Y CAGRn/m

EAGLE PHARMS INC recorded an outflow of $132K in free cash flow in Q2 2023, representing a cash shortfall after capex. This represents a decrease of 100.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$15.4M

YoY-58.0%

QoQ-29.9%

5Y CAGR-31.3%

10Y CAGR+3.6%

EAGLE PHARMS INC held $15.4M in cash against $61.9M in long-term debt as of Q2 2023.

Shares Outstanding

13M

YoY-2.2%

QoQ-0.8%

EAGLE PHARMS INC had 13M shares outstanding in Q2 2023. This represents a decrease of 2.2% from the same quarter a year earlier. Against the prior quarter it is down 0.8%.

Dividends Per Share

Not reported for Q2 2023.

Margins & Returns

Gross Margin

73.9%

YoY+2.5pp

QoQ0.0pp

5Y change+5.2pp

EAGLE PHARMS INC's gross margin was 73.9% in Q2 2023, indicating the percentage of revenue retained after direct costs. This is up 2.5 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.

Operating Margin

15.9%

YoY+13.0pp

QoQ-1.8pp

5Y change+15.6pp

EAGLE PHARMS INC's operating margin was 15.9% in Q2 2023, reflecting core business profitability. This is up 13.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.8 percentage points.

Net Margin

8.0%

YoY+20.7pp

QoQ-0.7pp

EAGLE PHARMS INC's net profit margin was 8.0% in Q2 2023, showing the share of revenue converted to profit. This is up 20.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.

Return on Equity

2.1%

YoY+6.0pp

QoQ-0.3pp

EAGLE PHARMS INC's quarterly ROE was 2.1% in Q2 2023: one quarter's net income over shareholder equity, not annualized. This is up 6.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.

Capital Allocation

R&D Spending

$9.8M

YoY-14.0%

QoQ+6.1%

EAGLE PHARMS INC invested $9.8M in research and development in Q2 2023. This represents a decrease of 14.0% from the same quarter a year earlier. Against the prior quarter it is up 6.1%.

Share Buybacks

YoYn/m

QoQn/m

EAGLE PHARMS INC repurchased no shares in Q2 2023. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Capital Expenditures

$6K

YoYn/m

QoQ-89.7%

5Y CAGRn/m

10Y CAGR-15.1%

EAGLE PHARMS INC invested $6K in capex in Q2 2023, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 89.7%.

EGRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EGRX quarterly income statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$257.6M	$316.6M+84.6%	$171.5M-8.7%	$187.8M-4.1%	$195.9M-8.2%	$213.3M-9.9%	$236.7M+24.9%	$189.5M+186.1%	$66.2M+246.8%	$19.1M+39.6%	$13.7M+438.8%	$2.5M
Cost of Revenue	$73.3M	$85.5M+171.1%	$31.5M-6.3%	$33.6M-29.7%	$47.9M+13.0%	$42.4M+25.7%	$33.7M-5.8%	$35.8M+128.7%	$15.6M+33.6%	$11.7M+58.7%	$7.4M+133.1%	$3.2M
Gross Profit	$184.3M	$231.2M+65.1%	$140.0M-9.2%	$154.2M+14.2%	$135.0M-10.8%	$151.4M-25.4%	$203.0M+32.1%	$153.7M+203.9%	$50.6M+584.9%	$7.4M+17.3%	$6.3Mn/m	-$627K
R&D Expenses	$35.6M	$34.1M-33.5%	$51.3M+66.6%	$30.8M-16.4%	$36.8M-17.1%	$44.4M+36.2%	$32.6M+15.3%	$28.3M+1.6%	$27.9M+65.6%	$16.8M+71.7%	$9.8M-23.5%	$12.8M
SG&A Expenses	$103.2M	$106.6M+41.6%	$75.3M-4.2%	$78.6M+2.9%	$76.4M+26.2%	$60.5M-15.3%	$71.4M+33.9%	$53.3M+164.5%	$20.2M+116.2%	$9.3M+88.1%	$5.0M-22.5%	$6.4M
Operating Income	$41.0M	$81.0M+2823.8%	$2.8M-91.6%	$33.0M+51.1%	$21.8M-40.4%	$36.6M-50.5%	$74.0M+38.7%	$53.4M+1984.0%	$2.6Mn/m	-$18.8Mn/m	-$8.5Mn/m	-$19.8M
EBITDA	N/A	$81.6M+2209.8%	$3.5M-89.6%	$33.8M+48.4%	$22.8M-39.7%	$37.8M-49.6%	$74.9M+38.8%	$54.0M+1920.7%	$2.7Mn/m	-$18.7Mn/m	-$8.3Mn/m	-$19.6M
Interest Expense	$6.1M	$4.0M+147.4%	$1.6M-36.6%	$2.6M-4.1%	$2.7M-1.8%	$2.7M+140.8%	$1.1M+14100.0%	$8K-27.3%	$11K+37.5%	$8K-97.4%	$309K+239.6%	$91K
Income Tax	$17.2M	$25.8M+532.3%	$4.1M-61.8%	$10.7M+39.1%	$7.7M+260.0%	$2.1M-89.8%	$21.0Mn/m	-$28.0M-934300.0%	$3Kn/m	-$1.3Mn/m	-$899Kn/m	-$781K
Net Income	$11.9M	$35.6Mn/m	-$8.6M-172.0%	$12.0M-16.2%	$14.3M-55.1%	$31.9M-38.6%	$51.9M-36.2%	$81.5M+3068.1%	$2.6Mn/m	-$18.0Mn/m	-$6.0Mn/m	-$19.4M
EPS (Basic)	N/A	$2.76n/m	-$0.66-174.2%	$0.89-14.4%	$1.04-51.9%	$2.16-37.2%	$3.44-34.4%	$5.24+2982.4%	$0.17	-$1.97	-$3.25n/m	-$14.11
EPS (Diluted)	$0.91	$2.73n/m	-$0.66-175.9%	$0.87-13.9%	$1.01-51.7%	$2.09-36.1%	$3.27-34.1%	$4.96+3000.0%	$0.16	-$1.97	-$3.25n/m	-$14.11
Diluted Shares (Avg)	N/A	13M+0.1%	13M-5.2%	14M-2.6%	14M-7.5%	15M-4.0%	16M-3.2%	16M+1.1%	16M	10M	3M	N/A

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Revenue	$64.6M-12.8%	$66.3M-42.8%	$60.7M+43.4%	$65.9M+65.4%	$74.1M+54.1%	$115.9M+180.9%	$42.3M-15.2%	$39.9M-20.2%
Cost of Revenue	$16.9M-20.4%	$17.3M-31.3%	$18.2M+88.2%	$20.9M+280.4%	$21.2M+167.8%	$25.2M+198.2%	$9.7M-1.5%	$5.5M-37.1%
Gross Profit	$47.8M-9.8%	$49.0M-46.0%	$42.5M+30.1%	$45.0M+31.0%	$53.0M+31.7%	$90.7M+176.5%	$32.6M-18.6%	$34.4M-16.6%
R&D Expenses	$9.8M-14.0%	$9.3M+51.8%	$7.2M+90.6%	$9.3M-60.0%	$11.4M+15.4%	$6.1M-57.3%	$3.8M-59.7%	$23.3M+382.4%
SG&A Expenses	$27.7M-24.9%	$28.0M+26.0%	$24.1M+18.8%	$23.5M+26.9%	$36.8M+121.4%	$22.2M+11.6%	$20.3M+11.8%	$18.5M+4.4%
Operating Income	$10.3M+367.7%	$11.8M-80.3%	$9.5M+60.5%	$9.5Mn/m	$2.2M-79.6%	$59.8Mn/m	$5.9M-39.8%	-$10.2M-166.0%
EBITDA	$10.4M+333.0%	$11.9M-80.2%	$9.5M+56.9%	$9.7Mn/m	$2.4M-78.2%	$60.0Mn/m	$6.1M-39.4%	-$10.0M-163.9%
Interest Expense	$1.4M+162.3%	$1.5M+314.2%	$2.0M+401.3%	$1.1M+189.6%	$552K+30.8%	$366K-13.3%	$395K-4.4%	$396K-19.0%
Income Tax	$4.1M+15.4%	$4.5M-67.1%	$5.1M-30.7%	$3.5Mn/m	$3.6M+85.0%	$13.6M+672.4%	$7.4M+122.8%	-$7.0M-477.2%
Net Income	$5.2Mn/m	$5.8M-86.9%	$8.2Mn/m	-$7.1Mn/m	-$9.4M-361.6%	$44.1Mn/m	-$6.2M-176.9%	-$5.6M-179.6%
EPS (Basic)	$0.39n/m	$0.44-87.3%	$0.63n/m	-$0.54n/m	-$0.74-364.3%	$3.47n/m	-$0.47-178.3%	-$0.43-182.7%
EPS (Diluted)	$0.39n/m	$0.44-87.1%	$0.62n/m	-$0.54n/m	-$0.74-374.1%	$3.41n/m	-$0.47-179.7%	-$0.43-184.3%
Diluted Shares (Avg)	13M+2.5%	13M+1.9%	N/A	13M+0.7%	13M-3.2%	13M-1.2%	N/A	13M-5.1%

EGRX Balance Sheet

EGRX quarterly balance sheet

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$406.2M+60.1%	$253.7M+0.2%	$253.2M-0.5%	$254.6M+6.7%	$238.6M-11.6%	$270.1M+26.0%	$214.3M+72.0%	$124.6M+133.3%	$53.4M+195.0%	$18.1M	N/A
Current Assets	$188.8M+9.4%	$172.6M+3.9%	$166.1M-7.5%	$179.4M+9.5%	$163.8M-13.2%	$188.7M+72.9%	$109.1M-10.8%	$122.3M+130.6%	$53.0M+203.3%	$17.5M	N/A
Cash & Equivalents	$55.3M-43.4%	$97.7M-5.3%	$103.2M-6.0%	$109.8M+39.3%	$78.8M-31.3%	$114.7M+117.1%	$52.8M-33.2%	$79.1M+248.0%	$22.7M+117.3%	$10.5M+106.4%	$5.1M
Short-Term Investments	$0-100.0%	$5.3Mn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$20.0Mn/m	$0n/m	$0
Inventory	$47.8M+118.2%	$21.9M+171.3%	$8.1M+23.0%	$6.6M-20.9%	$8.3M+62.3%	$5.1M+86.9%	$2.7M-81.8%	$15.0M+1062.4%	$1.3Mn/m	$0	N/A
Accounts Receivable	$72.4M+76.0%	$41.1M-19.5%	$51.1M+6.5%	$48.0M-27.8%	$66.5M+23.5%	$53.8M+27.6%	$42.2M+60.6%	$26.3M+260.0%	$7.3M+42.4%	$5.1M	N/A
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$45.0M+13.3%	$39.7M0.0%	$39.7M0.0%	$39.7M0.0%	$39.7M0.0%	$39.7M0.0%	$39.7Mn/m	$0	N/A	N/A	N/A
Total Liabilities	$172.6M+123.3%	$77.3M+15.0%	$67.2M-10.9%	$75.4M-3.2%	$77.8M-14.4%	$90.9M+44.1%	$63.1M+84.2%	$34.3M+68.7%	$20.3M-80.8%	$106.0M	N/A
Current Liabilities	$111.1M+49.4%	$74.4M+95.3%	$38.1M-1.9%	$38.8M-2.2%	$39.7M-16.1%	$47.3M+15.5%	$41.0M+19.6%	$34.3M+68.7%	$20.3M+41.6%	$14.3M	N/A
Non-Current Liabilities	$61.5M+2018.9%	$2.9M-90.0%	$29.1M-20.4%	$36.6M-4.2%	$38.2M-12.5%	$43.6M+97.1%	$22.1Mn/m	$0n/m	$0-100.0%	$91.7M	N/A
Long-Term Debt	$56.2M	N/A	$25.1M-25.1%	$33.6M-12.1%	$38.2M-11.1%	$42.9Mn/m	$0	N/A	N/A	N/A	N/A
Total Equity	$233.6M+32.4%	$176.5M-5.1%	$186.0M+3.8%	$179.2M+11.5%	$160.8M-10.3%	$179.1M+18.5%	$151.2M+67.4%	$90.3M+173.0%	$33.1Mn/m	-$87.9Mn/m	-$93.4M
Retained Earnings	$111.5M+47.0%	$75.9M-10.2%	$84.5M+16.5%	$72.5M+24.6%	$58.2M+121.4%	$26.3Mn/m	-$25.7Mn/m	-$107.1Mn/m	-$104.2Mn/m	-$102.1M	N/A

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Total Assets	$404.8M+6.0%	$414.2M+29.4%	$406.2M+60.1%	$386.4M+50.8%	$381.8M+44.5%	$320.2M+23.2%	$253.7M+0.2%	$256.3M+3.3%
Current Assets	$187.3M-3.7%	$192.5M-19.9%	$188.8M+9.4%	$185.0M+7.8%	$194.5M+10.8%	$240.2M+46.5%	$172.6M+3.9%	$171.7M+4.8%
Cash & Equivalents	$15.4M-58.0%	$21.9M-68.5%	$55.3M-43.4%	$15.4M-84.6%	$36.6M-66.4%	$69.5M-33.9%	$97.7M-5.3%	$99.7M+11.2%
Short-Term Investments	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$6.2Mn/m	$6.0Mn/m	$5.3Mn/m	$4.6Mn/m
Inventory	$42.5M-26.4%	$44.1M+77.9%	$47.8M+118.2%	$63.9M+585.5%	$57.7M+595.8%	$24.8M+261.7%	$21.9M+171.3%	$9.3M+41.4%
Accounts Receivable	$115.1M+34.0%	$115.0M-12.2%	$72.4M+76.0%	$96.9M+113.8%	$85.9M+63.2%	$130.9M+191.7%	$41.1M-19.5%	$45.3M-13.1%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Goodwill	$45.0M+4.6%	$45.0M+13.3%	$45.0M+13.3%	$41.8M+5.2%	$43.1M+8.3%	$39.7M0.0%	$39.7M0.0%	$39.7M0.0%
Total Liabilities	$152.8M+6.3%	$171.3M+64.4%	$172.6M+123.3%	$154.7M+117.9%	$143.8M+107.2%	$104.2M+51.3%	$77.3M+15.0%	$71.0M-5.8%
Current Liabilities	$86.6M-20.5%	$97.8M-3.8%	$111.1M+49.4%	$121.8M+151.5%	$109.0M+144.0%	$101.6M+142.2%	$74.4M+95.3%	$48.4M+6.4%
Non-Current Liabilities	$66.2M+90.0%	$73.5M+2768.6%	$61.5M+2018.9%	$32.8M+45.7%	$34.8M+40.8%	$2.6M-90.5%	$2.9M-90.0%	$22.5M-24.5%
Long-Term Debt	$61.9M+120.9%	$68.8M+186.8%	$56.2M	$26.4M+35.6%	$28.0M+31.1%	$24.0M+3.2%	N/A	$19.5M-27.9%
Total Equity	$252.0M+5.9%	$242.8M+12.4%	$233.6M+32.4%	$231.8M+25.1%	$238.0M+22.1%	$216.0M+13.0%	$176.5M-5.1%	$185.3M+7.2%
Retained Earnings	$122.4M+10.8%	$117.3M-2.2%	$111.5M+47.0%	$103.3M+25.9%	$110.5M+26.0%	$119.9M+42.6%	$75.9M-10.2%	$82.1M+7.4%

EGRX Cash Flow Statement

EGRX quarterly cash flow statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$9.3M	$50.7M+79.7%	$28.2M-43.0%	$49.5M-11.6%	$56.0M+6.9%	$52.4M-11.1%	$58.9M+10.7%	$53.2Mn/m	-$9.7Mn/m	-$13.8Mn/m	-$5.9Mn/m	-$15.5M
Depreciation & Amortization	N/A	$646K-15.4%	$764K-12.4%	$872K-10.3%	$972K-15.8%	$1.2M+23.9%	$932K+45.4%	$641K+472.3%	$112K+7.7%	$104K-23.0%	$135K-43.8%	$240K
Stock-Based Compensation	N/A	$16.5M-15.9%	$19.6M-21.0%	$24.8M+12.5%	$22.0M+15.3%	$19.1M+23.7%	$15.4M+58.0%	$9.8M+141.1%	$4.1M+568.5%	$606K+91.2%	$317K-21.1%	$402K
Capital Expenditures	$74K	$178K-44.9%	$323K-56.8%	$747K-3.9%	$777K+484.2%	$133K-97.0%	$4.4M+179.0%	$1.6M-15.5%	$1.9M+3989.1%	$46K+12.2%	$41K+24.2%	$33K
Free Cash Flow	-$9.4M	$50.5M+81.1%	$27.9M-42.8%	$48.8M-11.7%	$55.2M+5.7%	$52.3M-4.1%	$54.5M+5.6%	$51.6Mn/m	-$11.6Mn/m	-$13.9Mn/m	-$5.9Mn/m	-$15.6M
Investing Cash Flow	-$23.8M	-$86.8Mn/m	-$5.3Mn/m	-$18.2Mn/m	-$777Kn/m	-$133Kn/m	-$5.2Mn/m	-$45.8Mn/m	-$1.9Mn/m	-$20.0M-1473.9%	$1.5M-50.8%	$3.0M
Financing Cash Flow	$11.9M	-$6.2Mn/m	-$28.4Mn/m	-$37.9Mn/m	-$24.2Mn/m	-$88.1M-1187.3%	$8.1Mn/m	-$33.7M-160.3%	$55.8M+20.9%	$46.2M+370.5%	$9.8M+2.7%	$9.5M
Share Buybacks	$10.0M	$18.0M-15.1%	$21.2M-39.4%	$35.0M+94.9%	$18.0M-75.4%	$73.1M+66.9%	$43.8M+18.3%	$37.0Mn/m	$0n/m	$0	N/A	N/A

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Operating Cash Flow	-$126K-100.3%	-$33.5Mn/m	$37.6M+364.8%	-$13.2M-1340.6%	$43.0M+400.3%	-$16.6M-258.5%	$8.1M-59.1%	$1.1M-81.0%
Depreciation & Amortization	$100K-50.0%	$100K-50.0%	$146K-11.0%	$200K0.0%	$200K0.0%	$200K0.0%	$164K-24.1%	$200K+2.0%
Stock-Based Compensation	$4.2M-6.8%	$4.6M+8.0%	N/A	$3.5M-13.4%	$4.5M+5.1%	$4.3M-34.0%	N/A	$4.1M-13.5%
Capital Expenditures	$6Kn/m	$58K-65.5%	$10K-79.6%	$0-100.0%	$0-100.0%	$168K-56.3%	$49K-71.2%	$5K-97.5%
Free Cash Flow	-$132K-100.3%	-$33.6Mn/m	$37.5M+367.5%	-$13.2M-1346.4%	$43.0M+407.1%	-$16.8M-266.2%	$8.0M-59.0%	$1.1M-80.4%
Investing Cash Flow	-$6Kn/m	-$12.6Mn/m	-$9Kn/m	-$11.2Mn/m	-$75.4M-65679.1%	-$168Kn/m	-$49Kn/m	-$5Kn/m
Financing Cash Flow	-$6.4Mn/m	$12.6Mn/m	$2.4Mn/m	$3.3Mn/m	-$536Kn/m	-$11.4Mn/m	-$10.1Mn/m	-$10.0Mn/m
Share Buybacks	$0n/m	$0-100.0%	$0-100.0%	$10.0M+20.3%	$0-100.0%	$8.1M+462.4%	$8.6M+23.5%	$8.3M-64.0%

Not reported in any period shown, so not listed: Dividends Paid.

EGRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EGRX quarterly financial ratios

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	73.0%-8.6pp	81.6%-0.5pp	82.1%+13.2pp	68.9%-2.1pp	71.0%-14.8pp	85.8%+4.6pp	81.1%+4.7pp	76.4%+37.7pp	38.7%-7.4pp	46.0%+70.7pp	-24.7%
Operating Margin	25.6%+24.0pp	1.6%-15.9pp	17.5%+6.4pp	11.1%-6.0pp	17.2%-14.1pp	31.3%+3.1pp	28.2%+24.3pp	3.9%+102.1pp	-98.2%-36.4pp	-61.8%	-781.1%
Net Margin	11.3%+16.3pp	-5.0%-11.4pp	6.4%-0.9pp	7.3%-7.7pp	15.0%-7.0pp	21.9%-21.1pp	43.0%+39.1pp	3.9%+98.0pp	-94.1%-49.9pp	-44.2%	-763.4%
Return on Equity	15.3%+20.2pp	-4.9%-11.3pp	6.5%-1.5pp	8.0%-11.8pp	19.8%-9.2pp	29.0%-24.9pp	53.9%+51.0pp	2.9%+57.2pp	-54.3%	N/A	N/A
Return on Assets	8.8%+12.2pp	-3.4%-8.1pp	4.7%-0.9pp	5.6%-7.8pp	13.4%-5.9pp	19.2%-18.8pp	38.0%+35.9pp	2.1%+35.7pp	-33.7%-0.3pp	-33.4%	N/A
Current Ratio	1.70-0.6x	2.32-2.0x	4.36-0.3x	4.62+0.5x	4.13+0.1x	3.99+1.3x	2.66-0.9x	3.57+1.0x	2.61+1.4x	1.22	N/A
Debt-to-Equity	0.24	N/A	0.14-0.1x	0.19-0.1x	0.240.0x	0.24+0.2x	0.00	N/A	N/A	N/A	N/A
Liabilities-to-Equity	0.74+0.3x	0.44+0.1x	0.36-0.1x	0.42-0.1x	0.480.0x	0.51+0.1x	0.420.0x	0.38-0.2x	0.61	N/A	N/A
Asset Turnover	0.78+0.1x	0.68-0.1x	0.740.0x	0.77-0.1x	0.890.0x	0.880.0x	0.88+0.4x	0.53+0.2x	0.36-0.4x	0.76	N/A
FCF Margin	16.0%-0.3pp	16.3%-9.7pp	26.0%-2.2pp	28.2%+3.7pp	24.5%+1.5pp	23.0%-4.2pp	27.2%+44.8pp	-17.5%+55.2pp	-72.7%-29.4pp	-43.3%	-613.7%

Metric	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K	Q3'2110-Q
Gross Margin	73.9%+2.5pp	73.9%-4.4pp	70.0%-7.2pp	68.3%-17.9pp	71.4%-12.1pp	78.3%-1.3pp	77.1%-3.2pp	86.2%+3.7pp
Operating Margin	15.9%+13.0pp	17.8%-33.9pp	15.6%+1.7pp	14.4%+39.9pp	3.0%-19.5pp	51.6%+60.8pp	13.9%-5.7pp	-25.5%-56.4pp
Net Margin	8.0%+20.7pp	8.7%-29.3pp	13.5%+28.1pp	-10.8%+3.3pp	-12.8%-20.3pp	38.0%+39.0pp	-14.6%-30.8pp	-14.1%-28.2pp
Return on Equity	2.1%+6.0pp	2.4%-18.0pp	3.5%+7.0pp	-3.1%-0.1pp	-4.0%-5.8pp	20.4%+20.6pp	-3.5%-7.8pp	-3.0%-7.1pp
Return on Assets	1.3%+3.8pp	1.4%-12.4pp	2.0%+4.5pp	-1.8%+0.3pp	-2.5%-3.9pp	13.8%+13.9pp	-2.4%-5.6pp	-2.2%-5.0pp
Current Ratio	2.16+0.4x	1.97-0.4x	1.70-0.6x	1.52-2.0x	1.78-2.1x	2.36-1.5x	2.32-2.0x	3.55-0.1x
Debt-to-Equity	0.25+0.1x	0.28+0.2x	0.24	0.110.0x	0.120.0x	0.110.0x	N/A	0.11-0.1x
Liabilities-to-Equity	0.610.0x	0.71+0.2x	0.74+0.3x	0.67+0.3x	0.60+0.2x	0.48+0.1x	0.44+0.1x	0.38-0.1x
Asset Turnover	0.160.0x	0.16-0.2x	0.150.0x	0.170.0x	0.190.0x	0.36+0.2x	0.170.0x	0.160.0x
FCF Margin	-0.2%-58.2pp	-50.6%-36.1pp	61.9%+42.9pp	-20.1%-22.7pp	58.0%+40.4pp	-14.5%-39.0pp	19.0%-20.3pp	2.7%-8.2pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
EAGLE PHARMS INC EGRX	FY2022	$316.6M	$35.6M	11.3%	$3.3M	—
LEEF BRANDS INC LEEEF	FY2025	$34.8M	-$17.6M	-50.7%	$46.0M	—
HEALTHY EXTRACTS INC HYEX	FY2025	$4.5M	-$881K	-19.5%	$14.7M	—
RADNOSTIX INC INIS	FY2025	$13.1M	-$908K	-7.0%	$26.1M	—

Where EAGLE PHARMS INC Ranks

Frequently Asked Questions

What is EAGLE PHARMS INC's annual revenue?

EAGLE PHARMS INC (EGRX) reported $316.6M in total revenue for fiscal year 2022. This represents a 84.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is EAGLE PHARMS INC's revenue growing?

EAGLE PHARMS INC (EGRX) revenue grew by 84.6% year-over-year, from $171.5M to $316.6M in fiscal year 2022.

Is EAGLE PHARMS INC profitable?

Yes, EAGLE PHARMS INC (EGRX) reported a net income of $11.9M over the trailing 12 months to June 30, 2023. In fiscal year 2022 it reported a net income of $35.6M, with a net profit margin of 11.3%.

What is EAGLE PHARMS INC's EBITDA?

EAGLE PHARMS INC (EGRX) had EBITDA of $81.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does EAGLE PHARMS INC have?

As of fiscal year 2022, EAGLE PHARMS INC (EGRX) had $55.3M in cash and equivalents against $56.2M in long-term debt.

What is EAGLE PHARMS INC's gross margin?

EAGLE PHARMS INC (EGRX) had a gross margin of 73.0% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is EAGLE PHARMS INC's operating margin?

EAGLE PHARMS INC (EGRX) had an operating margin of 25.6% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

What is EAGLE PHARMS INC's net profit margin?

EAGLE PHARMS INC (EGRX) had a net profit margin of 11.3% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.

What is EAGLE PHARMS INC's return on equity (ROE)?

EAGLE PHARMS INC (EGRX) has a return on equity of 15.3% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.

What is EAGLE PHARMS INC's free cash flow?

EAGLE PHARMS INC (EGRX) generated $50.5M in free cash flow during fiscal year 2022. This represents a 81.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is EAGLE PHARMS INC's operating cash flow?

EAGLE PHARMS INC (EGRX) generated $50.7M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are EAGLE PHARMS INC's total assets?

EAGLE PHARMS INC (EGRX) had $406.2M in total assets as of fiscal year 2022, including both current and long-term assets.

What are EAGLE PHARMS INC's capital expenditures?

EAGLE PHARMS INC (EGRX) invested $178K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How much does EAGLE PHARMS INC spend on research and development?

EAGLE PHARMS INC (EGRX) invested $34.1M in research and development during fiscal year 2022.

Does EAGLE PHARMS INC buy back shares?

Yes, EAGLE PHARMS INC (EGRX) spent $18.0M on share buybacks during fiscal year 2022, returning capital to shareholders by reducing shares outstanding.

How many shares does EAGLE PHARMS INC have outstanding?

EAGLE PHARMS INC (EGRX) had 13M shares outstanding as of fiscal year 2022.

What is EAGLE PHARMS INC's current ratio?

EAGLE PHARMS INC (EGRX) had a current ratio of 1.70 as of fiscal year 2022, which is generally considered healthy.

What is EAGLE PHARMS INC's debt-to-equity ratio?

EAGLE PHARMS INC (EGRX) had a debt-to-equity ratio of 0.24 as of fiscal year 2022. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

What is EAGLE PHARMS INC's liabilities-to-equity ratio?

EAGLE PHARMS INC (EGRX) had a liabilities-to-equity ratio of 0.74 as of fiscal year 2022, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

What is EAGLE PHARMS INC's return on assets (ROA)?

EAGLE PHARMS INC (EGRX) had a return on assets of 8.8% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is EAGLE PHARMS INC's P/E ratio?

EAGLE PHARMS INC (EGRX) trades at 0.3x earnings, its market capitalization divided by $11.9M net income, trailing 12 months to June 30, 2023. The market capitalization is $3.3M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is EAGLE PHARMS INC's price-to-sales ratio?

EAGLE PHARMS INC (EGRX) trades at 0.0x sales, its market capitalization divided by $257.6M revenue, trailing 12 months to June 30, 2023. The market capitalization is $3.3M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is EAGLE PHARMS INC's Altman Z-Score?

EAGLE PHARMS INC (EGRX) has an Altman Z-Score of 2.06, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is EAGLE PHARMS INC's Piotroski F-Score?

EAGLE PHARMS INC (EGRX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are EAGLE PHARMS INC's earnings high quality?

EAGLE PHARMS INC (EGRX) has an earnings quality ratio of 1.42x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can EAGLE PHARMS INC cover its interest payments?

EAGLE PHARMS INC (EGRX) has an interest coverage ratio of 20.01x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.